AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

MARAGANORE JOHN purchased $249K of RAPP (indirect holdings)

MARAGANORE JOHN purchased 9,411 indirectly-held shares of Rapport Therapeutics, Inc. (RAPP) at an average of $26.45 ($26.38–$26.92, $0.25M total) across 2 trades on 2026-10-22.

Original reporting
SEC EDGAR · MARAGANORE JOHN
Published Oct 22, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Bullish
medium confidence
Mentioned
$RAPP
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPBullishLow
01

Why it matters

The director's purchase may provide a modest bullish cue, but the small size limits market reaction.

02

Market read

Insider buying by a director is a positive signal but modest in scale; traders may watch for follow‑up activity.

03

What to watch

Potential dilution from future financing rounds or upcoming clinical trial outcomes could outweigh the insider signal.

Relevance 5/10Novelty 4/10Timing: same-day filing

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$RAPPBullishMedium confidence
Context

Director John Maraganore purchased 9,411 shares of Rapport Therapeutics for $248,891, indicating insider confidence.

Expected impact

modest upside as market prices in director's confidence

Evidence & confidence

A director buying ~250k of stock is a material insider transaction, but the amount is modest relative to market cap, so impact is limited.

Market effects

Sector

Limited; reflects confidence in biotech sector but no broader impact.

Regional

None; transaction is company‑specific.

Global

Minimal; only relevant to investors in Rapport Therapeutics.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Company
    Rapport Therapeutics, Inc.

    Biotech firm developing therapeutic candidates.

  • Person
    John Maraganore

    Director of Rapport Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com